Replies to post #246138 on Biotech Values

[DewDiligence]

BAVA.CO is another competitor in RSV vaccines, although they are 1-2 years behind GSK and PFE (but about even with MRNA):

https://finance.yahoo.com/news/bavarian-nordic-completes-case-accrual-111600794.html

Bavarian Nordic A/S announced today that the Phase 3 clinical trial of MVA-BN RSV, the Company’s investigational vaccine for the prevention of respiratory syncytial virus (RSV) in adults ≥60 years of age, has now accrued the number of cases required to complete the primary efficacy analysis, which is expected around mid-2023. Adjudicated data have confirmed enough cases with both 2+ symptoms and 3+ symptoms as required in the trial.

The global, randomized, placebo-controlled, double-blind Phase 3 VANIR clinical trial has enrolled more than 20,000 participants across more than 100 centers in the U.S. and Germany. The primary objective of the study will assess the efficacy of the vaccine candidate against lower-respiratory tract disease (LTRD) caused by RSV.